Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.76 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.76 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401415 | 0.87 | PDGFRB (1.00) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL3884102 | 0.85 | PDGFRB (0.97) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL3426356 | 0.84 | PDGFRB (0.71) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL3909734 | 0.81 | PDGFRB (0.67) | PDGFRBPDGFRABRAFEGFRROCK1 | |
| SCHEMBL3906854 | 0.75 | PDGFRB (0.61) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL3915443 | 0.74 | PDGFRB (0.76) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL4640696 | 0.74 | PDGFRB (0.72) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL3916312 | 0.73 | PDGFRB (0.74) | PDGFRBPDGFRAMEN1KMT2APIK3CA | |
| SCHEMBL15256286 | 0.72 | PDGFRB (0.66) | PDGFRBPDGFRAMEN1KMT2APOLB | |
| SCHEMBL4544763 | 0.72 | KCNH3 (0.67) | MEN1KMT2APOLBPIK3CANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | AVENTIS PHARMACEUTICALS INC. | 2003-07-31 | — | — | US | claimed |
| EP-1133479-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | claimed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | claimed |
| WO-2000031050-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | claimed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | claimed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | claimed |
| US-7550597-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-08-18 | — | — | US | disclosed |
| US-6846815-B2 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | AVENTIS PHARMACEUTICALS INC. | 2003-07-31 | — | — | US | disclosed |
| US-6524347-B1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVANTIS PHARMACEUTICALS INC. | 2003-02-25 | — | — | US | disclosed |
| EP-1133479-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6159978-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCT, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0991628-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000031050-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-0991628-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054156-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182054-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, ABL1 | PDGFRB 39/4885PDGFRA 45/4885MEN1 3202/4885 |
| US-20030144284-A1 | Heterocyclic imines such as 2-anilino-6-quinoxalinol, used to suppress cell proliferation, differentiation, chemotaxis and/or activation; prophylaxis of restinosis; anticarcinogenic agents | LCK, NFATC1, MAP2K2 | PDGFRB 106/4885PDGFRA 299/4885MEN1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.